Inhibition of Rab1B Impairs Trafficking and Maturation of SARS-CoV-2 Spike Protein

Author:

Veeck Christopher1ORCID,Biedenkopf Nadine12ORCID,Rohde Cornelius12ORCID,Becker Stephan12ORCID,Halwe Sandro12

Affiliation:

1. Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany

2. German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) utilizes cellular trafficking pathways to process its structural proteins and move them to the site of assembly. Nevertheless, the exact process of assembly and subcellular trafficking of SARS-CoV-2 proteins remains largely unknown. Here, we have identified and characterized Rab1B as an important host factor for the trafficking and maturation of the spike protein (S) after synthesis at the endoplasmic reticulum (ER). Using confocal microscopy, we showed that S and Rab1B substantially colocalized in compartments of the early secretory pathway. Co-expression of dominant-negative (DN) Rab1B N121I leads to an aberrant distribution of S into perinuclear spots after ectopic expression and in SARS-CoV-2-infected cells caused by either structural rearrangement of the ERGIC or Golgi or missing interaction between Rab1B and S. Western blot analyses revealed a complete loss of the mature, cleaved S2 subunit in cell lysates and culture supernatants upon co-expression of DN Rab1B N121I. In sum, our studies indicate that Rab1B is an important regulator of trafficking and maturation of SARS-CoV-2 S, which not only improves our understanding of the coronavirus replication cycle but also may have implications for the development of antiviral strategies.

Funder

German Center of Infection Research

Deutsche Forschungsgemeinschaft

Pandemie Netzwerk Hessen

Coropan

Open Acess Publishing Fund of Philipps-Universität Marburg

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference51 articles.

1. World Health Organization (2021, June 14). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int.

2. Phase 2/3 Trial of Molnupiravir for Treatment of COVID-19 in Nonhospitalized Adults;Caraco;NEJM Evid.,2022

3. Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab;Gupta;N. Engl. J. Med.,2021

4. COVID-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports;Mahase;BMJ,2021

5. SARS-CoV-2 Antiviral Therapy;Tao;Clin. Microbiol. Rev.,2021

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3